Source:http://linkedlifedata.com/resource/pubmed/id/15313535
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2004-8-17
|
pubmed:abstractText |
Metallo-beta-lactamases (M beta L) were initially characterized in Japan, usually of the IMP-type, and found in Pseudomonas aeruginosa (PSA), Acinetobacter spp. (ACB), or Serratia marcescens (SM). The number of M beta L types has increased worldwide, but geographic dissemination within Japan has appeared limited. This study compares baseline levels of M beta L resistance from two 22-center studies (1996-1997) to the longitudinal sample (3 sites) of Japanese isolates from the SENTRY Antimicrobial Surveillance Program (1998-2002). All minimal inhibitory concentration results were determined by reference methods. A total of 26.8% PSA, 3.4% ACB, and 3.1% Enterobacteriaceae (enterobacters and SM) with resistance to monitored carbapenems (CARB) (minimal inhibitory concentration, > or =8 microg/mL) were screened for M beta L production by disk approximation tests (EDTA and 2-MPA inhibitors), CARB hydrolysis by enzyme extracts, and selected PCR primers for known M beta L types. All M beta L-positive strains (10) were sequenced to determine enzyme identification. Clonality in each center was determined by automated ribotyping and PFGE. The CARB susceptibility rates in PSA decreased (80.7% to 62.0%) over the monitored interval (1998-2002), but varied by medical center location. Among CARB-resistant isolates, 10.8% were attributed to M beta L strains (1.1% of all PSA tested). M beta L identification showed the following: five PSA (three IMP-1, two IMP-2), four SM (one IMP-1, two IMP-1 + OXA-1, and one IMP-11). Also a single ACB had an IMP-1. Eight of 10 M beta L isolations occurred between 2000 and 2002; four occurred in 2002. BRL42715, an AMP-C inhibitor, confirmed AMP-C-mediated resistance in 87.3% of PSA, and outer membrane protein changes were also discovered by membrane studies. Prior results (22 sites, 1997-1998) showed CARB resistance at 22.4-25.6% and 0.5-0.9% M beta Ls (IMP-1) overall; it was slightly elevated in this SENTRY Program sample. In conclusion, M beta L-producing strains from several species persist in Japan, but represent a distinct minority of all CARB-resistant strains (1998-2002). Although M beta L rates appear generally stable in Japan, continued surveillance for these mechanisms seems to be a prudent practice, because of the mobility of the genetic determinants and the emergence of novel enzyme types, especially among the Enterobacteriaceae.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0732-8893
|
pubmed:author |
pubmed-author:BellJan MJM,
pubmed-author:DeshpandeLalitagauri MLM,
pubmed-author:HirakataYoichiY,
pubmed-author:HirataYasuyoshiY,
pubmed-author:InoueMatsuhisaM,
pubmed-author:JonesRonald NRN,
pubmed-author:KawakamaSayokoS,
pubmed-author:KohnoShigeruS,
pubmed-author:MiyazawaYukihisaY,
pubmed-author:OnoYasuoY,
pubmed-author:TolemanMark AMA,
pubmed-author:TurnidgeJohn DJD
|
pubmed:issnType |
Print
|
pubmed:volume |
49
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
289-94
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15313535-Amino Acid Sequence,
pubmed-meshheading:15313535-Anti-Bacterial Agents,
pubmed-meshheading:15313535-Carbapenems,
pubmed-meshheading:15313535-Drug Resistance, Multiple, Bacterial,
pubmed-meshheading:15313535-Gram-Negative Bacteria,
pubmed-meshheading:15313535-Humans,
pubmed-meshheading:15313535-Japan,
pubmed-meshheading:15313535-Microbial Sensitivity Tests,
pubmed-meshheading:15313535-Molecular Sequence Data,
pubmed-meshheading:15313535-Population Surveillance,
pubmed-meshheading:15313535-beta-Lactamases
|
pubmed:year |
2004
|
pubmed:articleTitle |
Evaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002).
|
pubmed:affiliation |
The JONES Group/JMI Laboratories, North Liberty, IA, USA. ronald-jones@jmilabs.com
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|